Skip to main
PRME
PRME logo

PRME Stock Forecast & Price Target

PRME Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 36%
Hold 21%
Sell 0%
Strong Sell 0%

Bulls say

Prime Medicine Inc is highlighted for its promising future, with projected risk-adjusted revenues from its drug candidate PM577 anticipated to reach $980 million by 2035, growing significantly from $32 million in 2030. The company's advanced Prime Editing technology is aimed at addressing high unmet medical needs across a range of diseases, and upcoming clinical data, particularly for programs like PM359, is expected to demonstrate the potential advantages of this next-generation gene editing approach. Additionally, the recent progress in its in vivo gene editing initiatives, supported by strong preclinical data and funding for specific programs, positions Prime Medicine favorably within the biotechnology landscape.

Bears say

Prime Medicine's stock is facing a negative outlook due to uncertainties surrounding regulatory approval for its gene editing therapies, which could significantly impact projected financial metrics if these products do not receive the necessary endorsements. Additionally, challenges related to patient recruitment for clinical programs may hinder the company’s ability to advance its pipeline effectively, further exacerbating financial risks. Furthermore, pricing concerns regarding the affordability of Prime's therapies, combined with broader safety apprehensions associated with gene editing technologies, may limit market acceptance and overall financial performance.

PRME has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 36% recommend Buy, 21% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prime Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prime Medicine Inc (PRME) Forecast

Analysts have given PRME a Buy based on their latest research and market trends.

According to 14 analysts, PRME has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.96, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.96, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prime Medicine Inc (PRME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.